The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer

Advances in Immunology

Volumn 130, Issue , 2016, Pages 25-74

  Ward, Jeffrey P ^a   Gubin, Matthew M ^a   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer Immunoediting; Cancer immunotherapy; Checkpoint blockade immunotherapy; Neoantigens; Tumor specific mutant antigens

Indexed keywords

ANTIGEN; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; DENDRITIC CELL VACCINE; DNA VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; NEOANTIGEN; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; RNA VACCINE; SIPULEUCEL T; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ALGORITHM; BIOINFORMATICS; CANCER IMMUNOEDITING; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; GENOMICS; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; ANIMAL; CELL TRANSFORMATION; CELLULAR IMMUNITY; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; NEOPLASMS; PROCEDURES; TRENDS; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL TRANSFORMATION, NEOPLASTIC; GENOMICS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR MICROENVIRONMENT;

EID: 84957928309     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/bs.ai.2016.01.001     Document Type: Chapter

References (174)

1. Abelin J.G., Trantham P.D., Penny S.A., Patterson A.M., Ward S.T., Hildebrand W.H., Hunt D.F. Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. Nature Protocols 2015, 10(9):1308-1318. 10.1038/nprot.2015.086.
2. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Stratton M.R. Signatures of mutational processes in human cancer. Nature 2013, 500(7463):415-421. 10.1038/nature12477.
3. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274(5284):94-96.
4. Babbitt B.P., Allen P.M., Matsueda G., Haber E., Unanue E.R. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 1985, 317(6035):359-361.
5. Bakker A.B., Schreurs M.W., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., Figdor C.G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. Journal of Experimental Medicine 1994, 179(3):1005-1009.
6. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(7077):682-687. 10.1038/nature04444.
7. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohme I., Forsberg B., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. International Journal of Cancer 1995, 60(2):183-189.
8. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987, 329(6139):506-512. 10.1038/329506a0.
9. Blum J.S., Wearsch P.A., Cresswell P. Pathways of antigen processing. Annual Review of Immunology 2013, 31:443-473. 10.1146/annurev-immunol-032712-095910.
10. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Brahmer J.R. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England Journal of Medicine 2015, 373(17):1627-1639. 10.1056/NEJMoa1507643.
11. Braumuller H., Wieder T., Brenner E., Assmann S., Hahn M., Alkhaled M., Rocken M. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013, 494(7437):361-365. 10.1038/nature11824.
12. Brown S.D., Warren R.L., Gibb E.A., Martin S.D., Spinelli J.J., Nelson B.H., Holt R.A. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Research 2014, 24(5):743-750. 10.1101/gr.165985.113.
13. Burnet M. Cancer: A biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. British Medical Journal 1957, 1(5023):841-847.
14. Burnet F.M. The concept of immunological surveillance. Progress in Experimental Tumor Research 1970, 13:1-27.
15. Calis J.J., Maybeno M., Greenbaum J.A., Weiskopf D., De Silva A.D., Sette A., Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Computational Biology 2013, 9(10). 10.1371/journal.pcbi.1003266.
16. Cameron B.J., Gerry A.B., Dukes J., Harper J.V., Kannan V., Bianchi F.C., Jakobsen B.K. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Translational Medicine 2013, 5(197):197ra103. 10.1126/scitranslmed.3006034.
17. Carreno B.M., Magrini V., Becker-Hapak M., Kaabinejadian S., Hundal J., Petti A.A., Linette G.P. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 10.1126/science.aaa3828.
18. Castle J.C., Kreiter S., Diekmann J., Lower M., van de Roemer N., de Graaf J., Sahin U. Exploiting the mutanome for tumor vaccination. Cancer Research 2012, 72(5):1081-1091. 10.1158/0008-5472.CAN-11-3722.
19. Chandran S.S., Paria B.C., Srivastava A.K., Rothermel L.D., Stephens D.J., Dudley M.E., Kammula U.S. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clinical Cancer Research 2015, 21(3):534-543. 10.1158/1078-0432.CCR-14-2208.
20. Chauvin J.-M., Pagliano O., Fourcade J., Sun Z., Wang H., Sander C., Zarour H.M. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. The Journal of Clinical Investigation 2015, 125(5):2046-2058. 10.1172/JCI80445.
21. Chen D.S., Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39(1):1-10. 10.1016/j.immuni.2013.07.012.
22. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(5):1914-1918.
23. Cobbold M., De La Pena H., Norris A., Polefrone J.M., Qian J., English A.M., Engelhard V.H. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Science Translational Medicine 2013, 5(203):203ra125. 10.1126/scitranslmed.3006061.
24. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(17):7976-7980.
25. Coulie P.G., Van den Eynde B.J., van der Bruggen P., Boon T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nature Reviews. Cancer 2014, 14(2):135-146. 10.1038/nrc3670.
26. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Slingluff C.L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994, 264(5159):716-719.
27. De Backer O., Verheyden A.M., Martin B., Godelaine D., De Plaen E., Brasseur R., Boon T. Structure, chromosomal location, and expression pattern of three mouse genes homologous to the human MAGE genes. Genomics 1995, 28(1):74-83. 10.1006/geno.1995.1108.
28. De Plaen E., Lurquin C., Van Pel A., Mariame B., Szikora J.P., Wolfel T., Boon T. Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proceedings of the National Academy of Sciences of the United States of America 1988, 85(7):2274-2278.
29. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Schreiber R.D. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. The Journal of Experimental Medicine 2011, 208(10):1989-2003. 10.1084/jem.20101158.
30. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413(6852):165-171. 10.1038/35093109.
31. Dingjan T., Spendlove I., Durrant L.G., Scott A.M., Yuriev E., Ramsland P.A. Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. Molecular Immunology 2015, 67(2 Pt. A):75-88. 10.1016/j.molimm.2015.02.028.
32. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine 2002, 8(8):793-800. 10.1038/nm730.
33. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine 1999, 5(12):1365-1369. 10.1038/70932.
34. Draper L.M., Kwong M.L.M., Gros A., Stevanović S., Tran E., Kerkar S., Hinrichs C.S. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clinical Cancer Research 2015, 21(19):4431-4439. 10.1158/1078-0432.CCR-14-3341.
35. Dubey P., Hendrickson R.C., Meredith S.C., Siegel C.T., Shabanowitz J., Skipper J.C., Schreiber H. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. The Journal of Experimental Medicine 1997, 185(4):695-705.
36. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology 2002, 3(11):991-998. 10.1038/ni1102-991.
37. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21(2):137-148. 10.1016/j.immuni.2004.07.017.
38. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annual Review of Immunology 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803.
39. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482(7385):405-409. 10.1038/nature10803.
40. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde 1909, 5:273-290.
41. Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. The Journal of Experimental Medicine 1995, 181(6):2109-2117.
42. Foley E.J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Research 1953, 13(12):835-837.
43. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine 2000, 192(7):1027-1034.
44. Fritsch E.F., Rajasagi M., Ott P.A., Brusic V., Hacohen N., Wu C.J. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunology Research 2014, 2(6):522-529. 10.1158/2326-6066.CIR-13-0227.
45. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(alpha)+ dendritic cells. The Journal of Experimental Medicine 2011, 208(10):2005-2016. 10.1084/jem.20101159.
46. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964. 10.1126/science.1129139.
47. Gangadhar T.C., Vonderheide R.H. Mitigating the toxic effects of anticancer immunotherapy. Nature Reviews. Clinical Oncology 2014, 11(2):91-99. 10.1038/nrclinonc.2013.245.
48. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., Investigators K.- Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine 2015, 372(21):2018-2028. 10.1056/NEJMoa1501824.
49. Giguere S., Drouin A., Lacoste A., Marchand M., Corbeil J., Laviolette F. MHC-NP: Predicting peptides naturally processed by the MHC. Journal of Immunological Methods 2013, 400-401:30-36. 10.1016/j.jim.2013.10.003.
50. Gillis S., Smith K.A. Long term culture of tumour-specific cytotoxic T cells. Nature 1977, 268(5616):154-156.
51. Gjertsen M.K., Bakka A., Breivik J., Saeterdal I., Solheim B.G., Søreide O., Gaudernack G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995, 346(8987):1399-1400.
52. Greco G., Fruci D., Accapezzato D., Barnaba V., Nisini R., Alimena G., Tosi R. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996, 10(4):693-699.
53. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899. 10.1016/j.cell.2010.01.025.
54. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Research 1943, 3(5):326-333.
55. Gubin M.M., Artyomov M.N., Mardis E.R., Schreiber R.D. Tumor neoantigens: Building a framework for personalized cancer immunotherapy. The Journal of Clinical Investigation 2015, 125(9):3413-3421. 10.1172/JCI80008.
56. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Schreiber R.D. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515(7528):577-581. 10.1038/nature13988.
57. Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., Schumacher T.N. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nature Methods 2009, 6(7):520-526. 10.1038/nmeth.1345.
58. Hammer J., Bono E., Gallazzi F., Belunis C., Nagy Z., Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. The Journal of Experimental Medicine 1994, 180(6):2353-2358.
59. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013.
60. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. The EMBO Journal 2013, 32(2):194-203. 10.1038/emboj.2012.333.
61. Heidelberger C. Chemical carcinogenesis. Annual Review of Biochemistry 1975, 44:79-121. 10.1146/annurev.bi.44.070175.000455.
62. Herberman R.B., Holden H.T. Natural cell-mediated immunity. Advances in Cancer Research 1978, 27:305-377.
63. Herin M., Lemoine C., Weynants P., Vessiere F., Van Pel A., Knuth A., Boon T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. International Journal of Cancer 1987, 39(3):390-396.
64. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(8):4712-4717. 10.1073/pnas.0830997100.
65. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363(8):711-723. 10.1056/NEJMoa1003466.
66. Hunig T. T-cell function and specificity in athymic mice. Immunology Today 1983, 4(3):84-87. 10.1016/0167-5699(83)90125-1.
67. Hurwitz A.A., Yu T.F., Leach D.R., Allison J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(17):10067-10071.
68. Ikehara S., Pahwa R.N., Fernandes G., Hansen C.T., Good R.A. Functional T cells in athymic nude mice. Proceedings of the National Academy of Sciences of the United States of America 1984, 81(3):886-888.
69. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(19):12293-12297. 10.1073/pnas.192461099.
70. Jin D., Fan J., Wang L., Thompson L.F., Liu A., Daniel B.J., Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Research 2010, 70(6):2245-2255. 10.1158/0008-5472.CAN-09-3109.
71. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546. 10.1182/blood-2009-03-211714.
72. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Investigators I.S. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine 2010, 363(5):411-422. 10.1056/NEJMoa1001294.
73. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(13):7556-7561.
74. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(9):3515-3519.
75. Kenter G.G., Welters M.J.P., Valentijn A.R.P.M., Lowik M.J.G., Berends-van der Meer D.M.A., Vloon A.P.G., Melief C.J.M. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. The New England Journal of Medicine 2009, 361(19):1838-1847. 10.1056/NEJMoa0810097.
76. Kim Y., Sidney J., Pinilla C., Sette A., Peters B. Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinformatics 2009, 10:394. 10.1186/1471-2105-10-394.
77. Koboldt D.C., Steinberg K.M., Larson D.E., Wilson R.K., Mardis E.R. The next-generation sequencing revolution and its impact on genomics. Cell 2013, 155(1):27-38. 10.1016/j.cell.2013.09.006.
78. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450(7171):903-907. 10.1038/nature06309.
79. Kreiter S., Vormehr M., van de Roemer N., Diken M., Lower M., Diekmann J., Sahin U. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015, 10.1038/nature14426.
80. Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., Schumacher T.N. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Science Translational Medicine 2014, 6(254):254ra128. 10.1126/scitranslmed.3008918.
81. Kvistborg P., Shu C.J., Heemskerk B., Fankhauser M., Thrue C.A., Toebes M., Schumacher T.N.M. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. OncoImmunology 2012, 1(4):409-418.
82. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Freeman G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2001, 2(3):261-268. 10.1038/85330.
83. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Diaz L.A. PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine 2015, 372(26):2509-2520. 10.1056/NEJMoa1500596.
84. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-1736.
85. Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D., Wolfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(44):16013-16018. 10.1073/pnas.0500090102.
86. Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., Wilson R.K. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456(7218):66-72. 10.1038/nature07485.
87. Li Y., Depontieu F.R., Sidney J., Salay T.M., Engelhard V.H., Hunt D.F., Mariuzza R.A. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. Journal of Molecular Biology 2010, 399(4):596-603. 10.1016/j.jmb.2010.04.037.
88. Linard B., Bézieau S., Benlalam H., Labarrière N., Guilloux Y., Diez E., Jotereau F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. Journal of Immunology (Baltimore, Md.: 1950) 2002, 168(9):4802-4808.
89. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., June C.H. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122(6):863-871. 10.1182/blood-2013-03-490565.
90. Linnemann C., van Buuren M.M., Bies L., Verdegaal E.M., Schotte R., Calis J.J., Schumacher T.N. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature Medicine 2015, 21(1):81-85. 10.1038/nm.3773.
91. Loke P., Allison J.P. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(9):5336-5341. 10.1073/pnas.0931259100.
92. Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., Nielsen M. NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Research 2008, 36(Web Server issue):W509-W512. 10.1093/nar/gkn202.
93. Maby P., Tougeron D., Hamieh M., Mlecnik B., Kora H., Bindea G., Latouche J.-B. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: A rationale for personalized immunotherapy. Cancer Research 2015, 75(17):3446-3455. 10.1158/0008-5472.CAN-14-3051.
94. MacKie R.M., Reid R., Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. The New England Journal of Medicine 2003, 348(6):567-568. 10.1056/NEJM200302063480620.
95. Maleckar J.R., Sherman L.A. The composition of the T cell receptor repertoire in nude mice. The Journal of Immunology 1987, 138(11):3873-3876.
96. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444. 10.1038/nature07205.
97. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Schreiber R.D. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482(7385):400-404. 10.1038/nature10755.
98. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489. 10.1038/nature10673.
99. Mittal D., Gubin M.M., Schreiber R.D., Smyth M.J. New insights into cancer immunoediting and its three component phases-Elimination, equilibrium and escape. Current Opinion in Immunology 2014, 27:16-25. 10.1016/j.coi.2014.01.004.
100. Mohammed F., Cobbold M., Zarling A.L., Salim M., Barrett-Wilt G.A., Shabanowitz J., Willcox B.E. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: A molecular basis for the presentation of transformed self. Nature Immunology 2008, 9(11):1236-1243. 10.1038/ni.1660.
101. Monach P.A., Meredith S.C., Siegel C.T., Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995, 2(1):45-59.
102. Nielsen M., Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009, 10:296. 10.1186/1471-2105-10-296.
103. Nielsen M., Lundegaard C., Blicher T., Lamberth K., Harndahl M., Justesen S., Buus S. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007, 2(8). 10.1371/journal.pone.0000796.
104. Nielsen M., Lundegaard C., Lund O., Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005, 57(1-2):33-41. 10.1007/s00251-005-0781-7.
105. Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Science 2003, 12(5):1007-1017. 10.1110/ps.0239403.
106. Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95(1):286-293.
107. Old L.J. Cancer immunology: The search for specificity. National Cancer Institute Monograph 1982, 60:193-209.
108. Ono M., Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconjugate Journal 2004, 20(1):71-78. 10.1023/B:GLYC.0000018019.22070.7d.
109. O'Sullivan T., Saddawi-Konefka R., Vermi W., Koebel C.M., Arthur C., White J.M., Bui J.D. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. The Journal of Experimental Medicine 2012, 209(10):1869-1882. 10.1084/jem.20112738.
110. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 2012, 12(4):252-264. 10.1038/nrc3239.
111. Penn I. Posttransplant malignancies. Transplantation Proceedings 1999, 31(1-2):1260-1262.
112. Peters B., Bulik S., Tampe R., Van Endert P.M., Holzhutter H.G. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. The Journal of Immunology 2003, 171(4):1741-1749.
113. Peters B., Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005, 6(1):132. 10.1186/1471-2105-6-132.
114. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. Journal of the National Cancer Institute 1957, 18(6):769-778.
115. Radvanyi L.G., Bernatchez C., Zhang M., Fox P.S., Miller P., Chacon J., Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research 2012, 18(24):6758-6770. 10.1158/1078-0432.CCR-12-1177.
116. Rajasagi M., Shukla S.A., Fritsch E.F., Keskin D.B., DeLuca D., Carmona E., Wu C.J. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124(3):453-462. 10.1182/blood-2014-04-567933.
117. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999, 50(3-4):213-219.
118. Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J., Yannelli J.R., Rosenberg S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. Journal of the National Cancer Institute 1996, 88(2):100-108.
119. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Chan T.A. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.) 2015, aaa1348. 10.1126/science.aaa1348.
120. Robbins P.F., Lu Y.-C., El-Gamil M., Li Y.F., Gross C., Gartner J., Rosenberg S.A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine 2013, 19(6):747-752. 10.1038/nm.3161.
121. Roberts A., Perera S., Lang B., Vincent A., Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985, 317(6039):737-739.
122. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78(5):761-771.
123. Rooney M.S., Shukla S.A., Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160(1-2):48-61. 10.1016/j.cell.2014.12.033.
124. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. The New England Journal of Medicine 1988, 319(25):1676-1680. 10.1056/NEJM198812223192527.
125. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nature Medicine 2004, 10(9):909-915. 10.1038/nm1100.
126. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research 2011, 17(13):4550-4557. 10.1158/1078-0432.CCR-11-0116.
127. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570. 10.1126/science.1203486.
128. Schumacher T., Bunse L., Pusch S., Sahm F., Wiestler B., Quandt J., Platten M. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, 512(7514):324-327. 10.1038/nature13387.
129. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science (New York, N.Y.) 2015, 348(6230):69-74. 10.1126/science.aaa4971.
130. Segal N.H., Parsons D.W., Peggs K.S., Velculescu V., Kinzler K.W., Vogelstein B., Allison J.P. Epitope landscape in breast and colorectal cancer. Cancer Research 2008, 68(3):889-892. 10.1158/0008-5472.CAN-07-3095.
131. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410(6832):1107-1111. 10.1038/35074122.
132. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161(2):205-214. 10.1016/j.cell.2015.03.030.
133. Shukla S.A., Rooney M.S., Rajasagi M., Tiao G., Dixon P.M., Lawrence M.S., Getz G. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nature Biotechnology 2015, 33(11):1152-1158. 10.1038/nbt.3344.
134. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nature Reviews. Cancer 2005, 5(8):615-625. 10.1038/nrc1669.
135. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. The Journal of Experimental Medicine 2001, 193(6):661-670.
136. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunology 2001, 2(4):293-299. 10.1038/86297.
137. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. The Journal of Experimental Medicine 2000, 191(4):661-668.
138. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Chan T.A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine 2014, 371(23):2189-2199. 10.1056/NEJMoa1406498.
139. Somasundaram R., Swoboda R., Caputo L., Otvos L., Weber B., Volpe P., Herlyn D. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Research 2006, 66(6):3287-3293. 10.1158/0008-5472.CAN-05-1932.
140. Spranger S., Spaapen R.M., Zha Y., Williams J., Meng Y., Ha T.T., Gajewski T.F. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science Translational Medicine 2013, 5(200):200ra116. 10.1126/scitranslmed.3006504.
141. Stevanović S., Draper L.M., Langhan M.M., Campbell T.E., Kwong M.L., Wunderlich J.R., Hinrichs C.S. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. Journal of Clinical Oncology 2015, 33(14):1543-1550. 10.1200/JCO.2014.58.9093.
142. Stone J.D., Harris D.T., Kranz D.M. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity. Current Opinion in Immunology 2015, 33:16-22. 10.1016/j.coi.2015.01.003.
143. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97(1):192-197.
144. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183(4124):534-536.
145. Stutman O. Chemical carcinogenesis in nude mice: Comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. Journal of the National Cancer Institute 1979, 62(2):353-358.
146. Teng M.W.L., Galon J., Fridman W.H., Smyth M.J. From mice to humans: Developments in cancer immunoediting. The Journal of Clinical Investigation 2015, 125(9):3338-3346. 10.1172/JCI80004.
147. Teng M.W., Vesely M.D., Duret H., McLaughlin N., Towne J.E., Schreiber R.D., Smyth M.J. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Research 2012, 72(16):3987-3996. 10.1158/0008-5472.CAN-12-1337.
148. Thomas L. Delayed hypersensitivity in health and disease. Cellular and humoral aspects of the hypersensitive states 1959, 529-532. Hoeber-Harper, New York. H.S. Lawrence (Ed.).
149. Tran E., Ahmadzadeh M., Lu Y.-C., Gros A., Turcotte S., Robbins P.F., Rosenberg S.A. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science (New York, N.Y.) 2015, 350(6266):1387-1390. 10.1126/science.aad1253.
150. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.-C., Dudley M.E., Rosenberg S.A. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, N.Y.) 2014, 344(6184):641-645. 10.1126/science.1251102.
151. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J.M., Robert L., Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571. 10.1038/nature13954.
152. Van Allen E.M., Miao D., Schilling B., Shukla S.A., Blank C., Zimmer L., Garraway L.A. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (New York, N.Y.) 2015, 350(6257):207-211. 10.1126/science.aad0095.
153. van Buuren M.M., Calis J.J., Schumacher T.N. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. OncoImmunology 2014, 3:e28836. 10.4161/onci.28836.
154. Van den Eynde B., Hainaut P., Herin M., Knuth A., Lemoine C., Weynants P., Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. International Journal of Cancer 1989, 44(4):634-640.
155. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254(5038):1643-1647.
156. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. The Journal of Experimental Medicine 1999, 190(3):355-366.
157. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., Allison J.P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. The Journal of Experimental Medicine 2001, 194(4):481-489.
158. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., Schumacher T.N. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. Journal of Clinical Oncology 2013, 31(32):e439-e442. 10.1200/JCO.2012.47.7521.
159. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., Brichard V.G. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. Journal of Clinical Oncology 2013, 31(19):2396-2403. 10.1200/JCO.2012.43.7103.
160. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annual Review of Immunology 2011, 29:235-271. 10.1146/annurev-immunol-031210-101324.
161. Vita R., Overton J.A., Greenbaum J.A., Ponomarenko J., Clark J.D., Cantrell J.R., Peters B. The immune epitope database (IEDB) 3.0. Nucleic Acids Research 2015, 43(Database issue):D405-D412. 10.1093/nar/gku938.
162. Wang R.F., Robbins P.F., Kawakami Y., Kang X.Q., Rosenberg S.A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. Journal of Experimental Medicine 1995, 181(2):799-804.
163. Wang L., Rubinstein R., Lines J.L., Wasiuk A., Ahonen C., Guo Y., Noelle R.J. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. The Journal of Experimental Medicine 2011, 208(3):577-592. 10.1084/jem.20100619.
164. Watanabe N., Gavrieli M., Sedy J.R., Yang J., Fallarino F., Loftin S.K., Murphy K.M. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunology 2003, 4(7):670-679. 10.1038/ni944.
165. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270(5238):985-988.
166. Wedén S., Klemp M., Gladhaug I.P., Møller M., Eriksen J.A., Gaudernack G., Buanes T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. International Journal of Cancer 2011, 128(5):1120-1128. 10.1002/ijc.25449.
167. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269(5228):1281-1284.
168. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318(5853):1108-1113. 10.1126/science.1145720.
169. Yadav M., Jhunjhunwala S., Phung Q.T., Lupardus P., Tanguay J., Bumbaca S., Delamarre L. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515(7528):572-576. 10.1038/nature14001.
170. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews. Cancer 2009, 9(11):798-809. 10.1038/nrc2734.
171. Zarling A.L., Ficarro S.B., White F.M., Shabanowitz J., Hunt D.F., Engelhard V.H. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. Journal of Experimental Medicine 2000, 192(12):1755-1762.
172. Zarling A.L., Obeng R.C., Desch A.N., Pinczewski J., Cummings K.L., Deacon D.H., Engelhard V.H. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer. Cancer Research 2014, 74(23):6784-6795. 10.1158/0008-5472.CAN-14-0043.
173. Zarling A.L., Polefrone J.M., Evans A.M., Mikesh L.M., Shabanowitz J., Lewis S.T., Hunt D.F. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(40):14889-14894. 10.1073/pnas.0604045103.
174. Zhou J., Dudley M.E., Rosenberg S.A., Robbins P.F. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. Journal of Immunotherapy 2005, 28(1):53-62.